| 产品名称： | WIL2-NS |
|---|---|
| 商品货号： | TS210665 |
| Organism： | Homo sapiens, human |
| Tissue： | spleen |
| Cell Type： | B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain Epstein-Barr virus
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | hereditary spherocytosis |
| Age： | 5 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | transfection host |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The line was derived from the WIL-2 B cell line. |
| Clinical Data： | male Caucasian 5 years |
| Comments： | This line does not secrete immunoglobulin. The line was derived from the WIL-2 B cell line. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11 D16S539: 11,12 D5S818: 12,13 D7S820: 9,12 F13A01: 6,7 F13B: 10 FESFPS: 11,12 LPL: 9,10 THO1: 8,9.3 TPOX: 8,11 vWA: 17,20 |
| Name of Depositor： | TA Coons |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Levy JA, et al. Human lymphoblastoid lines from lymph node and spleen. Cancer 22: 517-524, 1968. PubMed: 5673231 Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sjogrens syndrome. J. Clin. Invest. 55: 1067-1073, 1975. PubMed: 804494 Vaughan JH, et al. Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen. US Patent 4,654,419 dated Mar 31 1987 Vaughan JH, et al. Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides. US Patent 5,116,725 dated May 26 1992 Vaughan JH, et al. Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides. US Patent 5,122,448 dated Jun 16 1992 Levy JA, et al. Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines. J. Natl. Cancer Inst. 46: 647-654, 1971. PubMed: 4323138 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | WIL2-NS |
|---|---|
| 商品货号： | TS210665 |
| Organism： | Homo sapiens, human |
| Tissue： | spleen |
| Cell Type： | B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain Epstein-Barr virus
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | hereditary spherocytosis |
| Age： | 5 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | transfection host |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The line was derived from the WIL-2 B cell line. |
| Clinical Data： | male Caucasian 5 years |
| Comments： | This line does not secrete immunoglobulin. The line was derived from the WIL-2 B cell line. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11 D16S539: 11,12 D5S818: 12,13 D7S820: 9,12 F13A01: 6,7 F13B: 10 FESFPS: 11,12 LPL: 9,10 THO1: 8,9.3 TPOX: 8,11 vWA: 17,20 |
| Name of Depositor： | TA Coons |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Levy JA, et al. Human lymphoblastoid lines from lymph node and spleen. Cancer 22: 517-524, 1968. PubMed: 5673231 Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sjogrens syndrome. J. Clin. Invest. 55: 1067-1073, 1975. PubMed: 804494 Vaughan JH, et al. Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen. US Patent 4,654,419 dated Mar 31 1987 Vaughan JH, et al. Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides. US Patent 5,116,725 dated May 26 1992 Vaughan JH, et al. Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides. US Patent 5,122,448 dated Jun 16 1992 Levy JA, et al. Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines. J. Natl. Cancer Inst. 46: 647-654, 1971. PubMed: 4323138 |
